473 results about "Brain damage" patented technology

The invention relates to hydrogel for treating ischemic brain injury and a preparation method thereof. The hydrogel is prepared from the following raw materials: methylacryloylated hyaluronic acid, methylacryloylated gelatin, curcumin loaded HA-PPS (Hydroxypropyl-Polyphenylene Sulfite) nano-micelles and dendrobium polysaccharide loaded sodium alginate microspheres. Through combination of a nanotechnology and an intelligent response material, HA-PPS is adopted to load curcumin and sodium alginate microspheres are adopted to encapsulate dendrobium polysaccharide, so that the drug activity can be more effectively protected, the drug is protected to penetrate through a blood brain barrier and be accurately delivered to a brain injury area, and targeted release of the drug is realized; the anti-oxidation and anti-inflammatory effects are better under the combined action of the curcumin and the dendrobium polysaccharides, and meanwhile, a slow release function is also achieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

The invention discloses application and a preparation method of exosome EGF-FGF-EXO containing double growth factors, the exosome EGF-FGF-EXO is uniform in particle size, high in loading efficiency and good in biological activity, the double growth factors comprise an epidermal growth factor EGF and a fibroblast growth factor FGF, and the epidermal growth factor EGF and the fibroblast growth factor FGF are added into the exosome EGF-FGF. The preparation method of the exosome EGF-FGF-EXO comprises preparation of an induced pluripotent stem cell (iPSC) exosome and loading of EGF-FGF, a recombinant epidermal growth factor (EGF) and a fibroblast growth factor (FGF) are loaded on the exosome from iPS-clone 12c, and the exosome product which has high biological activity and is used for treating nervous system diseases of neuroinflammation is prepared. The invention develops a brand new technical path for treatment of nervous system diseases, and in the fields of epilepsy, neurodegenerative diseases, brain injury and the like, the life quality of patients can be improved and important theoretical basis and technical support can be provided for precise medical treatment of nervous system diseases by precisely regulating and controlling neuroinflammation.

The invention discloses a method, a system and equipment for evaluating the treatment effect of CGRP on epilepsy or brain injury caused by epilepsy. It is found for the first time that CGRP inhibits expression of P2RX7 by inhibiting a JAK-STAT1 pathway so as to play a role in treating epilepsy or brain injury caused by epilepsy. On the basis, the invention provides a method, a system and equipment for evaluating the treatment effect of the CGRP on the epilepsy or the brain injury caused by the epilepsy for the field, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the epilepsy or the brain injury caused by the epilepsy, and a clinician is guided to formulate an individualized treatment scheme for the patient.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention provides a cheese protein hydrolysate as well as a preparation method and application thereof. The composition of the casein hydrolysate at least comprises at least one of a peptide fragment 1 with an amino acid sequence as shown in SEQ ID NO: 1, a peptide fragment 2 with an amino acid sequence as shown in SEQ ID NO: 2 and a peptide fragment 3 with an amino acid sequence as shown in SEQ ID NO: 3. The casein hydrolysate has good neuron protection and repair effects, and can improve cholinergic neuron and dopaminergic neuron damage; abeta protein deposition can be inhibited, so that neuronal synaptic disorder, neuronal apoptosis and brain injury caused by Abeta protein deposition are relieved; the cholinergic defect can be improved, so that the nerve development damage and the behavior and movement disorder caused by the cholinergic defect are relieved; and damaged neurons in hippocampus and hypothalamus can be repaired, so that the brain environment is kept stable.

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.

The invention belongs to the technical field of damage assessment, and particularly relates to a construction method of a rat traumatic brain injury model caused by explosive shock waves. By protecting other important visceral organs except the brain, interference of damage of visceral organs such as the lung to brain injury is avoided, the overall function stability of the body is maintained, the caused brain injury can more truly reflect the characteristics of explosive traumatic brain injury, and the credibility and repeatability of experimental data are improved. The construction method simulates loading of explosion shock wave parameters in a real environment, constructs an animal traumatic brain injury model through live ammunition explosion, is closer to an actual combat environment, and can truly reflect physical parameters related to explosion and a complex action process generated by interaction of the physical parameters. And a support is provided for developing molecular mechanisms of explosive traumatic brain injury, clinical diagnosis, screening of therapeutic drugs and the like.

A method for analyzing brain imaging data from a brain lesion patient and generating prognostic information is disclosed. The method includes obtaining imaging data of the brain of a patient from a scanner and classifying the data by acquisition plane and modality to select a data series of interest. The method further involves processing the data series of interest to generate brain masks and corresponding volumetric data. The brain masks and corresponding volumetric data are then co-registered to a common brain space, and registered volumetric data is generated. Lesion segmentation is performed to generate a lesion mask in the common brain space. The lesion mask data is applied to a trained prognostic model, which comprises a machine learning model configured to output a probability-based prognosis of the patient's brain lesion.

The BAG3 proteins are useful in the treatment of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Lewy body disease, vascular dementia, mixed dementia and traumatic brain injury, such as chronic traumatic encephalopathy (CTE). A therapeutic BAG3 composition, use of BAG3, and a method of treatment of BAG3 are described.

The present invention belongs to the field of rehabilitation therapy technology and discloses a longitudinal analysis method and system for magnetic resonance imaging data of mild brain injury. The method extracts BOLD signals from the magnetic resonance imaging data of subjects; constructs a symmetric positive definite sparse brain functional connectivity network set of subjects based on sparse inverse covariance matrix estimation; determines the brain functional connectivity network dictionary and sparse coefficient matrix in kernel space based on Riemannian manifold sparse coding; performs spatial distribution analysis of brain functional connectivity atomic networks; and performs longitudinal analysis of magnetic resonance imaging data of mild brain injury. By analyzing the differences in the spatial distribution of these highly present brain functional connectivity atomic networks in the brain, the present invention digs out brain functional connectivity imaging markers for distinguishing the three mild brain injury rehabilitation treatment stages: acute phase, subacute phase, and complete recovery, thereby realizing longitudinal analysis of the mild brain injury rehabilitation process.

Novel compounds of the structural formula (I), and pharmaceutically acceptable salts, hydrates and solvates thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.

The invention provides a brain injury prediction method and prediction system based on a multivariate feature fusion framework, and relates to the technical field of deep learning. In order to solve the problem that dynamic characteristics and static characteristics cannot be effectively fused when multivariate data damage prediction is carried out by adopting a nonlinear regression method in the prior art, dynamic characteristic data, static characteristic data, dynamic mechanical effect parameters, static influence effect parameters and brain damage degree data under various working conditions of a vehicle are obtained. A dynamic mechanical effect parameter is used as output to train a dynamic prediction model, accurate extraction of a dynamic feature time sequence rule can be ensured, a static influence effect parameter is used as output to ensure extraction of a static feature structured rule, and finally a dynamic feature vector and a static feature vector are used as input of a fusion prediction model. Fusion of a dynamic time sequence rule and a static structured rule is achieved, it is ensured that the two types of features are fully fused, and the prediction result is more accurate.

The invention relates to compounds, compositions, and methods for derepressing RE1 silencing transcription factor (REST) target genes are provided. In particular, a peptide having the sequence TEDLEPPEPPLPKEN (SEQ. ID NO: 1) and EDLEPPEPPLPK (SEQ. ID NO: 15), or the reversed sequences made of D-amino acids (retro inverted, RI) nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), are disclosed for inhibiting REST activity. The peptides are useful to treat, prevent, or ameliorate conditions such as traumatic brain injury, epilepsy, dementia, Huntington's Disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer; diabetes, and peripheral nerve injury.

A method for treating or reducing a likelihood of hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates utilizes a relative high dose of nasally administered insulin. In one aspect, the method includes intranasally administering, to a neonate in need thereof, an effective dose of insulin comprising between 350 U to 2000 U insulin.

The invention discloses a monoclonal antibody composition for resisting neurofilament light chain protein and application, the monoclonal antibody composition comprises NfL-Clone 1 and NfL-Clone 2, the amino acid sequence of a heavy chain variable region of the NfL-Clone 1 is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the NfL-Clone 1 is as shown in SEQ ID NO.2; the amino acid sequence of a heavy chain variable region of the NfL-Clone 2 is as shown in SEQ ID NO.3, and the amino acid sequence of a light chain variable region of the NfL-Clone 2 is as shown in SEQ ID NO.4. The antibody combination has the characteristics of specificity and high affinity, the NfL can be used as a brain injury biomarker, and meanwhile, the invention also provides a diagnostic detection kit of the antibody for early diagnosis of brain injury of a patient, so that the specificity and sensitivity of a diagnostic reagent are improved.

The present disclosure generally relates to methods and formulations for treating central nervous system (CNS) disorders. The present disclosure involves intranasal delivery of at least one antioxidant compound, allowing for effective treatment of a central nervous system disorder such as traumatic brain injury or stroke.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The invention discloses a silk fibroin-hyaluronic acid temperature-sensitive bioactive hydrogel scaffold, a preparation method thereof and application of the silk fibroin-hyaluronic acid temperature-sensitive bioactive hydrogel scaffold in TBI treatment, hyaluronic acid, silk fibroin and N-isopropylacrylamide are used as raw materials to construct temperature-sensitive hydrogel, and bone marrow mesenchymal stem cells (BMSCs) and paeoniflorin (PF) are loaded to form a treatment unit. Hyaluronic acid is one of components of an extracellular matrix (ECM), has high affinity to cells, and can promote proliferation of stem cells. Silk fibroin has high biocompatibility and biodegradability and good mechanical strength and ductility / toughness, and can promote tissue repair and stem cell attachment and proliferation. N-isopropylacrylamide endows the hydrogel with the characteristic of in-situ temperature-sensitive gelling. Therefore, the bioactive hydrogel stent has the advantages of components, combines the BMSCs and the PF, overcomes the obstacle that the medicine is limited by BBB to be transferred into the brain, and is implanted into a brain injury part after a TBI surgical operation to be used for repairing and treating nerve injury.

The invention relates to the technical field of walnut protein peptide modification, in particular to preparation and application of novel walnut intelligence-improving peptide, which mainly utilizes polyphenol-mediated Maillard covalent modification to weaken the bitter taste of walnut protein peptide, and controls the addition amount, reaction temperature, reaction time, pH and other external conditions of the walnut protein peptide to obtain the novel walnut intelligence-improving peptide. Screening the walnut protein intelligence-improving peptide by using indexes such as sensory evaluation and anti-oxidation characteristics; then, the influence of the modified walnut protein peptide on D-galactose induced brain injury model mice is deeply explored. Finally, the polyphenol-mediated Maillard reaction covalently modified walnut protein peptide powder is prepared by virtue of the technology, and the ingredient greatly increases the application of the walnut protein peptide in brain-strengthening and intelligence-improving products for alleviating brain injury and the like. The bitter taste of the walnut protein peptide obtained by the method is greatly reduced, and the walnut protein peptide has a potential brain protection effect.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses application of sodium butyrate in preparation of a medicine for relieving brain injury caused by gas explosion, the sodium butyrate regulates nerve cell ferroptosis through a JNK / P38 MAPK pathway to relieve the brain injury caused by gas explosion, firstly, an animal model of rat brain injury caused by gas explosion is established, and the relation between NaB and brain tissue neuron injury is intervened and observed by applying NaB; secondly, a shock wave physiotherapy instrument is used for impacting a co-culture system of three cells of CTX, H19-7 and GMI-R to simulate explosion to construct an in-vitro experimental model, P38, ERK and Fer-1 inhibitors are adopted for intervention, iron metabolism, ferroptosis and MAPK signal channel factor changes are observed from the cell and molecular level, a mechanism for inhibiting ferroptosis through a related cascade signal channel mediated by NaB-mediated intestinal-brain axis regulation and control is clarified, and the effect of inhibiting ferroptosis is achieved. And a theoretical basis is provided for further explaining the action mechanism of the gas explosion brain injury.

To provide 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase.SOLUTION: Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the present invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating nNOS-associated diseases and disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, as well as amyotrophic lateral sclerosis, cerebral palsy, stroke / ischemic brain injury, and migraine headaches.SELECTED DRAWING: Figure 1

The invention relates to a bionic nano CO generator as well as preparation and application thereof, belongs to the technical field of medicines, and solves the problem that a CO delivery system which can synergistically promote neuroprotection and neurogenesis and has brain targeting and controlled release capabilities is urgently required to be developed at present. According to the technical scheme, the bionic nano CO generator comprises a drug-loaded particle inner core and a covering film, the drug-loaded particle inner core comprises hollow mesoporous CeO2 nano particles and MnCO loaded on the hollow mesoporous CeO2 nano particles, and the covering film is a macrophage membrane and wraps the drug-loaded particle inner core. The compound is used for apoplexy treatment administration by integrating neuroprotection and enhancing innovative dual channels of endogenous nerve growth, and is expected to significantly reduce brain injury after cerebral apoplexy and restore neurological functions so as to relieve the worry about high death rate and long-term disability after cerebral ischemia-reperfusion injury.

The invention relates to an asparagine endopeptidase inhibitor neuronal targeting liposome and a preparation method thereof. The liposome comprises the following components: lecithin, cholesterol, phospholipid polyethylene glycol polypeptide, a fluorescent dye and an asparagine endopeptidase inhibitor. The preparation method has relatively good drug loading capacity and entrapment efficiency; after being atomized and dosed through a nose, the nebulizer can smoothly enter the brain of a mouse through a blood brain barrier to be distributed, and has good biocompatibility; according to the invention, DNA damage and ROS reaction of irradiated brain neurons and glial cells can be reduced, and the research and development value and important academic significance of the liposome for assisting in improving radiation brain injury are revealed.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention relates to a nutritional composition comprising a combination of (i) omega-3 fatty acid DHA with (ii) vitamin B2 and (iii) vitamin D3 and one or more from (iv) choline or a salt thereof and / or choline esters; and (v) dietary fibres and / or dietary butyrate for use in the treatment of neurodegenerative diseases and / or neurotrauma, brain injury and / or brain damage. The invention also relates to a composition comprising a combination of DHA, vitamin B2, vitamin D3 with one or more from (iv) choline or a salt thereof and / or choline esters; and (v) dietary fibres and / or dietary butyrate.

Novel compounds of the structural formula (I), and pharmaceutically acceptable salts, hydrates and solvates thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.

The invention discloses a bionic bacterial outer membrane nano-particle for drug delivery. The bionic bacterial outer membrane nano-particle is characterized by comprising low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out, and low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out; the medicine carrying liposome is prepared from phosphatidylcholine, cholesterol and DSPE-PEG2000 (Distearoyl Phosphatidylcholine-Polyethylene Glycol 2000) according to a preset mass ratio; the low-toxicity outer membrane vesicles and the drug-loaded liposome are subjected to ultrasonic assistance and 100nm filter membrane extrusion to obtain bionic bacterial outer membrane nanoparticles, the average particle size of the bionic bacterial outer membrane nanoparticles is about 100nm, and the encapsulation efficiency exceeds 85%. The BM-NPs system disclosed by the invention can load small molecule compounds, proteins, nucleic acids and gene therapy vectors, and is suitable for various central nervous system diseases such as spinal cord injury, cerebral apoplexy, traumatic brain injury, ischemia-reperfusion injury and the like.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.